Journal of Hepatocellular Carcinoma

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Addressing Global Differences in HCC Risk Factors and Management Strategies" in the Journal of Hepatocellular Carcinoma.

The Journal of Hepatocellular Carcinoma solicits papers addressing global diversity in HCC risk factors and their effect on outcomes. Although significant advances have been made in multidisciplinary and individualized screening and treatments for HCC, such sophisticated methods are relatively expensive and therefore remain beyond the reach of many patients in less economically developed countries where local resources and healthcare budget are limited. To address the global differences in treatment provision, the journal Editors are seeking to publish multidisciplinary clinical and translational studies, cost-effective screening and treatment strategies and consensus statements, including those which consider available local resources. 

Please contact Cassie Houtz at [email protected] with any queries.

Please view the journal Aims and Scope and author submission guidelines. The deadline for submissions is 1 December 2025.

Please submit your manuscript on our website, quoting the promo code UIPMT for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

The Journal of Hepatocellular Carcinoma is pleased to announce an upcoming Article Collection dedicated to the transformative role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have significantly impacted the treatment landscape for HCC. By blocking the signals that prevent T-cells from attacking cancer cells, these inhibitors enhance the immune system's ability to combat tumors. These therapies have shown potential in improving survival rates, reducing tumor burden, and providing durable responses in patients who previously had few effective options.

Given the impact and continued role of immune checkpoint inhibitors in treating HCC, we welcome submissions of original research articles, reviews, and perspectives that contribute to the understanding and advancement of these therapies. Of particular interest would be:

1. Papers focusing on peri-operative immunotherapy approaches in early-stage HCC to improve resectability, induce pathologic responses at time of surgery, and/or reduce rate of recurrence after resection.
2. Papers related to the intermediate/advanced HCC setting focusing on potential mechanisms of:

• Resistance to immunotherapy in advanced HCC based on different risk factor, e.g. viral vs. non-viral related HCC and MASH-related HCC.
• Synergy between immunotherapy and targeted and other systemic therapies.
• Synergy between immunotherapy and localized therapy approaches to improve response rates and survival outcomes.

This Article Collection will be included in a wider Game Changer Series focused on breakthrough therapies across medicine. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis and Dove Medical Press, increasing the discoverability and visibility of your research.

Please view the journal Aims and Scope and author submission guidelines. The deadline for submissions is 1 April 2026.

Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, enter the code SDSZG when prompted during submission.

Please contact Commissioning Editor Cassie Houtz at [email protected] with any questions.

View all papers in this article collection